RLMD - Relmada Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Coral Gables,
United States
Type: Equity
RLMD price evolution
RLMD
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.09 | $6.7 | $14.47 | $28.89 |
| Short term investments | $92.23 | $99.57 | $104.06 | $103.55 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $97.51 | $109.1 | $122 | $135.53 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.04 | $0.05 | $0.03 | $0.03 |
| Total investments | $92.23 | $99.57 | $104.06 | $103.55 |
| Total assets | $97.55 | $109.15 | $122.04 | $135.57 |
| Current liabilities | ||||
| Accounts payable | $3.51 | $2.86 | $4.85 | $4.42 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $12.19 | $8.42 | $10.7 | $10.1 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $12.19 | $8.42 | $10.7 | $10.1 |
| Shareholders' equity | ||||
| Retained earnings | -$560.9 | -$535.74 | -$513.74 | -$488.43 |
| Other shareholder equity | ||||
| Total shareholder equity | $85.36 | $100.73 | $111.34 | $125.47 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.09 | $5.4 | $44.44 | $2.5 |
| Short term investments | $92.23 | $142.93 | $167.47 | $114.6 |
| Net receivables | $0.51 | $0.09 | $0.17 | |
| Inventory | ||||
| Total current assets | $97.51 | $152.87 | $223.3 | $118.07 |
| Long term investments | ||||
| Property, plant & equipment | $0 | |||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.04 | $0.03 | $0.03 | $0.11 |
| Total investments | $92.23 | $142.93 | $167.47 | $114.6 |
| Total assets | $97.55 | $152.91 | $223.33 | $118.19 |
| Current liabilities | ||||
| Accounts payable | $3.51 | $5.26 | $11.19 | $8.35 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $12.19 | $12.47 | $15.06 | $12.6 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $12.19 | $12.47 | $15.06 | $12.6 |
| Shareholders' equity | ||||
| Retained earnings | -$560.9 | -$462.11 | -$305.07 | -$179.32 |
| Other shareholder equity | ||||
| Total shareholder equity | $85.36 | $140.44 | $208.26 | $105.58 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $14.75 | $10.45 | $15.86 | |
| Selling, general & administrative | $12.08 | $12.24 | $12.29 | |
| Total operating expenses | $26.83 | $22.69 | $28.15 | |
| Operating income | -$26.83 | -$22.69 | -$28.15 | |
| Income from continuing operations | ||||
| EBIT | -$25.17 | -$22 | -$26.32 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$25.17 | -$22 | -$26.32 | |
| Income (for common shares) | -$25.17 | -$22 | -$26.32 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $54.81 | $113.32 | $90.62 | $35.97 |
| Selling, general & administrative | $48.89 | $47.93 | $35.08 | $24.87 |
| Total operating expenses | $103.7 | $161.25 | $125.7 | $60.84 |
| Operating income | -$103.7 | -$161.25 | -$125.7 | -$60.84 |
| Income from continuing operations | ||||
| EBIT | -$98.79 | -$157.04 | -$125.75 | -$58.06 |
| Income tax expense | ||||
| Interest expense | $1.4 | |||
| Net income | ||||
| Net income | -$98.79 | -$157.04 | -$125.75 | -$59.46 |
| Income (for common shares) | -$98.79 | -$157.04 | -$125.75 | -$59.46 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$25.17 | -$22 | -$25.3 | -$26.32 |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.89 | $11.39 | $11.17 | $11.35 |
| Total cash flows from operations | -$10.25 | -$11.63 | -$13.27 | -$16.51 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $7.74 | $3.86 | -$1.15 | $40 |
| Total cash flows from investing | $7.74 | $3.86 | -$1.15 | $40 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$0.1 | |||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.61 | -$7.77 | -$14.43 | $23.5 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$98.79 | -$157.04 | -$125.75 | -$59.46 |
| Operating activities | ||||
| Depreciation | $0 | $0 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $43.81 | $44.19 | $40.49 | $20.78 |
| Total cash flows from operations | -$51.66 | -$103.8 | -$91.87 | -$27.81 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | $50.45 | $19.73 | -$54.12 | -$34.45 |
| Total cash flows from investing | $50.45 | $19.73 | -$54.12 | -$34.45 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $43.43 | $185.31 | $20.53 | |
| Net borrowings | -$0.11 | |||
| Total cash flows from financing | -$0.1 | $45.02 | $187.94 | $28.47 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$1.3 | -$39.05 | $41.95 | -$33.78 |
News
Fundamentals
| Market cap | $116.18M |
|---|---|
| Enterprise value | $112.09M |
| Shares outstanding | 30.10M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 1.36 |
| Book/Share | 2.84 |
| Cash/Share | 0.14 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.14 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 8.00 |
| Quick ratio | 8.00 |